Entrada Therapeutics, Inc. (NASDAQ:TRDA) just released its latest annual results and things are looking bullish. Entrada Therapeutics delivered a significant beat to revenue and earnings per share ...

Entrada Therapeutics can plough on with the development of its Duchenne muscular dystrophy (DMD) therapy, ENTR-601-44, now ...

Roth MKM analyst Boobalan Pachaiyappan lowered the firm’s price target on Entrada Therapeutics (TRDA) to $23 from $29 and keeps a Buy rating on ...

Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...

Analysts at William Blair issued their Q1 2026 earnings estimates for shares of Entrada Therapeutics in a report issued on Thursday, February 27th. William Blair analyst M. Minter expects that the ...

In a report released today, Francois Brisebois from Oppenheimer reiterated a Buy rating on Entrada Therapeutics Inc (TRDA – Research Report), ...

Millions of Americans tune into award shows like the Oscars, Emmys, Grammys, and Tonys every single year. Yet, you may not ...

Entrada Therapeutics' innovative Endosomal Escape Vehicle platform, poised to revolutionize drug delivery. Click here to read ...

Shares of Entrada Therapeutics rose after regulators removed a clinical hold and said its lead product candidate could be studied as a treatment for Duchenne muscular dystrophy. The stock was up 9.5% ...

Entrada Therapeutics (NASDAQ:TRDA – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have ...

TEL AVIV, Israel (AP) — Israel dice que detiene la entrada de todas las mercancías y suministros a Gaza.